Approval Probability 71%
TA Base Rate26%
Adjusted LOA41%
ML RiskLOW_RISK
| NCT ID | Title | Phase | Status | Enrollment | Velocity | Design | Start | Completion | Last Updated | Sites | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|
| NCT03432923 | A Study to Determine the Efficacy and Safety of a Benzocaine Lozenge for Treatment of Sore Throat. | PHASE3 | COMPLETED | 260 | — | — | Feb 2, 2018 | Apr 21, 2018 | Oct 18, 2018 | 19 | Russia |
A timer is started upon the intake of a single dose and stopped when the subject considers he/she has experienced meaningful pain relief.
| Arm | Type | Description |
|---|---|---|
| Benzocaine 8 mg | EXPERIMENTAL | Benzocaine 8 mg, oval, white to slightly beige to yellow film coated tablet. One lozenge to be dissolved slowly in the mouth every 2 hours. Max 6 per day, max treatment 5 days. |
| Placebo | PLACEBO_COMPARATOR | Placebo, oval, white to slightly beige to yellow film coated tablet. One lozenge to be dissolved slowly in the mouth every 2 hours. Max 6 per day, max treatment 5 days. |
| Name | Type | Description |
|---|---|---|
| Benzocaine 8 mg | DRUG | Benzocaine 8 mg, oval, white to slightly beige to yellow film coated tablet. One lozenge to be dissolved slowly in the mouth every 2 hours. Max 6 per day, max treatment 5 days. |
| Placebo | DRUG | Placebo, oval, white to slightly beige to yellow film coated tablet. One lozenge to be dissolved slowly in the mouth every 2 hours. Max 6 per day, max treatment 5 days. |
Subject Inclusion Criteria Subjects must meet all of the following inclusion criteria to be eligible for enrollment into the study: 1. Subjects of 18 years of age or older, suffering from throat pain caused by acute upper respiratory tract infection; 2. Symptoms of acute throat pain have been pers...